ACADIA Pharmaceuticals Inc. Stock News

Acadia (ACAD) delivered earnings and revenue surprises of -4% and 1.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 3 0 1

Here are the five best biotech ETFs to invest in right now.

Today, we are circling back on mid-cap biopharma ACADIA Pharmaceuticals Inc. for the first time since the spring of 2021. The company had one major disappointment in 2022, but has some potential new d

Axsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The Sunosi deal and promising pipeline bode well. Stiff competition in the target market remains a woe.

Mizuho has decided to maintain its Neutral rating of ACADIA Pharmaceuticals (NASDAQ:ACAD) and lower its price target from $17.00 to $15.00. Shares of ACADIA Pharmaceuticals are trading up 0.71% over t

SAN DIEGO--( BUSINESS WIRE )--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Acadia released its Q322 earnings this week. Revenues of $131m and a net loss of $27.2m are about par for the course. Acadia's only approved drug Nuplazid is approved to treat Parkinson's Disease Psyc

Upgrades Citigroup upgraded the previous rating for Advanced Energy Industries Inc (NASDAQ:AEIS) from Neutral to Buy. For the third quarter, Advanced Energy Indus had an EPS of $2.12, compared to yea

Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.

ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Mark Johnson - VP, IR Stephen Davis - CEO & Director Brendan Teehan - EVP,

Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?